Literature DB >> 16723598

Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study.

James A Karlowsky1, Daryl J Hoban, Melanie R Decorby, Nancy M Laing, George G Zhanel.   

Abstract

Ciprofloxacin-resistant Escherichia coli isolates (n = 1,858) from outpatient midstream urine specimens at 40 North American clinical laboratories in 2004 to 2005 were frequently resistant to ampicillin (79.8% of isolates) and trimethoprim-sulfamethoxazole (66.5%); concurrent resistance to cefdinir (9.0%) or nitrofurantoin (4.0%) was less common. Only 10.8% of isolates were resistant to ciprofloxacin alone. Fluoroquinolone-resistant isolates of E. coli from urine were frequently multidrug resistant.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723598      PMCID： PMC1479132          DOI： 10.1128/AAC.00123-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Survey on antibiotic usage in the treatment of urinary tract infections.

Authors:  K G Naber
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

Review 2.  Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.

Authors:  K Gupta; T M Hooton; W E Stamm
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

3.  Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000.

Authors:  D F Sahm; C Thornsberry; D C Mayfield; M E Jones; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

Authors:  J W Warren; E Abrutyn; J R Hebel; J R Johnson; A J Schaeffer; W E Stamm
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

5.  National patterns in the treatment of urinary tract infections in women by ambulatory care physicians.

Authors:  Elbert S Huang; Randall S Stafford
Journal:  Arch Intern Med       Date:  2002-01-14

6.  Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Authors:  E Lautenbach; B L Strom; W B Bilker; J B Patel; P H Edelstein; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-09-14       Impact factor: 9.079

7.  Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.

Authors:  James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Alan T Evangelista; Ian A Critchley; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2002-01       Impact factor: 5.283

8.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

Authors:  D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

9.  A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group.

Authors:  G G Zhanel; J A Karlowsky; G K Harding; A Carrie; T Mazzulli; D E Low; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191
View more
  44 in total

Review 1.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

2.  Peri-procedural povidone-iodine rectal preparation reduces microorganism counts and infectious complications following ultrasound-guided needle biopsy of the prostate.

Authors:  Justin R Gyorfi; Christopher Otteni; Kevin Brown; Amar Patel; Kathleen Lehman; Brett E Phillips; Kalyan Dewan; Girish Kirimanjeswara; Jay D Raman
Journal:  World J Urol       Date:  2014-03-30       Impact factor: 4.226

3.  Antimicrobial stewardship in daily practice: Managing an important resource.

Authors:  Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

4.  Fluoroquinolone antimicrobial drugs.

Authors:  Tiffany Chan; Paul E Bunce
Journal:  CMAJ       Date:  2017-05-01       Impact factor: 8.262

Review 5.  Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Authors:  Laurel K Mydock-McGrane; Thomas J Hannan; James W Janetka
Journal:  Expert Opin Drug Discov       Date:  2017-06-02       Impact factor: 6.098

6.  Discovery of nicoyamycin A, an inhibitor of uropathogenic Escherichia coli growth in low iron environments.

Authors:  Laura A Mike; Ashootosh Tripathi; Connor M Blankenship; Alyssa Saluk; Pamela J Schultz; Giselle Tamayo-Castillo; David H Sherman; Harry L T Mobley
Journal:  Chem Commun (Camb)       Date:  2017-11-28       Impact factor: 6.222

7.  Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.

Authors:  James A McKinnell; Nicholas S Stollenwerk; Chin W Jung; Loren G Miller
Journal:  Mayo Clin Proc       Date:  2011-05-16       Impact factor: 7.616

8.  Plasmid-mediated fluoroquinolone resistance determinants in Escherichia coli from community uncomplicated urinary tract infection in an area of high prevalence of quinolone resistance.

Authors:  C Longhi; M P Conte; M Marazzato; V Iebba; V Totino; F Santangelo; C Gallinelli; L Pallecchi; E Riccobono; S Schippa; A Comanducci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

9.  Extraintestinal Pathogenic and Antimicrobial-Resistant Escherichia coli Contamination of 56 Public Restrooms in the Greater Minneapolis-St. Paul Metropolitan Area.

Authors:  Muhanad Mohamed; Kris Owens; Abby Gajewski; Connie Clabots; Brian Johnston; Paul Thuras; Michael A Kuskowski; James R Johnson
Journal:  Appl Environ Microbiol       Date:  2015-04-24       Impact factor: 4.792

10.  High-throughput identification of chemical inhibitors of E. coli Group 2 capsule biogenesis as anti-virulence agents.

Authors:  Carlos C Goller; Patrick C Seed
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.